Evaluation of the utility of bone scan index (BSI) in the prediction of therapeutic effect of breast cancer patient with bone metastasis treated by zoledronic acid

Trial Profile

Evaluation of the utility of bone scan index (BSI) in the prediction of therapeutic effect of breast cancer patient with bone metastasis treated by zoledronic acid

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2013

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Advanced breast cancer; Bone metastases
  • Focus Pharmacodynamics
  • Most Recent Events

    • 27 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top